KalVista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $46.2M
Founded date: 2004
Investors 4
| Date | Name | Website |
| - | InterWest ... | interwest.... |
| - | RA Capital... | racap.com |
| - | Technology... | pivotcente... |
| - | Vivo Capit... | vivocapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 22.07.2015 | Series B | $33M | - |
| 23.08.2011 | Series A | $13.2M | - |
Mentions in press and media 11
| Date | Title | Description |
| 17.07.2026 | Eli Lilly to acquire BIOG portfolio company, AtaiBeckley Inc. | Eli Lilly to acquire BIOG portfolio company, AtaiBeckley Inc. Fri, Jul 17, 2026 08:00 CET Report this content 17 July 2026 THE BIOTECH GROWTH TRUST PLC (“BIOG” or the "Company") Eli Lilly to acquire BIOG portfolio company, AtaiBec... |
| 12.03.2025 | Shift Bioscience announces key appointments to advance rejuvenation therapeutics pipeline | Jill Reckless (CEO, RxCelerate) appointed as Translation Advisor Laurence Reid joins as Non-Executive Director, previously Decibel Therapeutics, Warp Drive Bio, Alnylam, and Millennium Pharmaceuticals Cambridge, UK, 12 March 2025: Shift Bio... |
| 27.10.2022 | KalVista Pharmaceuticals to Present Data at the 2022 American College of Allergy, Asthma & Immunology | KalVista today announced the acceptance of multiple abstracts at the 2022 Annual Scientific Meeting for the American College of Allergy, Asthma & Immunology. KalVista Pharmaceuticals (NASDAQ:KALV) CAMBRIDGE, MA, USA, October 27, 2022 /E... |
| 08.01.2022 | KalVista Pharmaceuticals : Corporate Presentation January 2022 | Corporate Overview January 2022 Forward-Looking Statements This presentation and the accompanying oral presentation contain "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securiti... |
| 16.11.2021 | KalVista Pharmaceuticals : Corporate Presentation November 2021 | Corporate Presentation November 2021 Forward-Looking Statements This presentation and the accompanying oral presentation contain "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Sec... |
| 09.09.2021 | KalVista Pharmaceuticals : Corporate Presentation September 2021 | Corporate Presentation September 2021 Forward-Looking Statements This presentation and the accompanying oral presentation contain "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Se... |
| 19.03.2021 | KalVista Pharmaceuticals Appoints Nancy Stuart to Board of Directors | CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Mar 19, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule... |
| 11.03.2021 | KalVista Pharmaceuticals Reports Third Fiscal Quarter Results | CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Mar 11, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule... |
| 22.07.2015 | Daily funding roundup - July 22, 2015 | Events.com has now raised a total of $17M; Darktrace landed $22.5M; Kinetic Social closed $17.5M Events.com has raised a new round of funding. The size of the round was undisclosed, but it was led by Arctaris and with participation from La ... |
| 22.07.2015 | KalVista Pharmaceuticals Raises $33M in Series B Financing | KalVista Pharmaceuticals, a Porton Down, UK-based research-led pharmaceutical company, raised $33m in Series B financing. Backers included Novo A/S, SV Life Sciences, RA Capital Management, Longwood Fund and Venrock. In conjunction with the... |
Show more